ESR1 and breast cancer: The selection and outgrowth of breast cancers resistant to endocrine therapy is common and most deaths arising from breast cancer are found in patients with ERα+ tumors.25 Moreover, in ERα+ breast cancers, one-third of women treated with tamoxifen for a period of 5 years will develop a recurrent disease within 15 years.